Molecular basis of macrolide-lincosamide-streptogramin (MLS) resistance in Finegoldia magna clinical isolates

Anaerobe. 2020 Aug:64:102220. doi: 10.1016/j.anaerobe.2020.102220. Epub 2020 Jun 10.

Abstract

Of 69 clinical isolates of Finegoldia magna tested, 36% presented high-level MICs of erythromycin (>256 μg/ml), harboring erm(A) (n = 20) or erm(B) (n=5). Of nine isolates exhibiting an inducible resistance phenotype to macrolides-lincosamides-streptogramins B, four (44%) were susceptible with a potential risk of treatment failure due to emergence of resistant mutants.

Keywords: F. magna; GPAC; MLS; anaerobes; clindamycin; erm(A); erm(B).

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins / genetics
  • DNA, Bacterial / genetics
  • Drug Resistance, Multiple, Bacterial / genetics*
  • Female
  • Firmicutes / drug effects*
  • Firmicutes / genetics*
  • Firmicutes / isolation & purification
  • Gram-Positive Bacterial Infections / diagnosis
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Lincosamides / pharmacology*
  • Macrolides / pharmacology*
  • Male
  • Methyltransferases / genetics*
  • Middle Aged
  • RNA, Ribosomal, 23S / genetics
  • Streptogramins / pharmacology*
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • DNA, Bacterial
  • Lincosamides
  • Macrolides
  • RNA, Ribosomal, 23S
  • Streptogramins
  • Methyltransferases
  • rRNA (adenosine-O-2'-)methyltransferase

Supplementary concepts

  • Finegoldia magna